Biogen (BIIB) reported $9.9B in revenue for fiscal 2025, +2.2% year on year. That ranks #508 by revenue among 2853 SEC filers and #54 in Healthcare. Net income was $1.3B, a net margin of 13.1%. Revenue has grown 4.9% a year on average since 2011 ($5.0B then). The fiscal 2025 balance sheet shows $29.4B in total assets, $3.0B in cash and $6.3B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $9.9B | +2.2% | FY20252025-12-31 |
| Gross profitGrossProfit | $11.6B | −6.3% | FY20202020-12-31 |
| Operating incomeIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | $1.6B | −18.3% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $1.3B | −20.8% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $2.2B | −23.3% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $154M | +0.1% | FY20252025-12-31 |
| Total assetsAssets | $29.4B | +5.0% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest | $18.3B | +9.2% | FY20252025-12-31 |
| CashCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | $3.0B | +26.7% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $6.3B | +38.3% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $2.5B | $320M | Open → |
| Q2 20262026-06-30 | $2.7B | $97.5M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 44 of 161 companies compared | 13.1% | |
| Operating marginRank 53 of 160 companies compared | 15.7% | |
| R&D as share of revenueRank 30 of 102 companies compared | 18.0% | |
| Cash as share of revenueRank 23 of 160 companies compared | 30.4% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Biogen Inc.
- Ticker
- BIIB
- Exchange
- Nasdaq
- SIC classification
- Biological Products, (No Diagnostic Substances) (2836)
- Fiscal year end
- 12-31
- CIK
- 0000875045
Filings
- 10-QJul 29, 2026Open filing →
- 10-QApr 29, 2026Open filing →
- 10-KFeb 6, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| AlconALC | $10.4B | $980M |
| Bausch Health CompaniesBHC | $10.3B | $157M |
| Intuitive SurgicalISRG | $10.1B | $2.9B |
| BiogenBIIB | $9.9B | $1.3B |
| ZoetisZTS | $9.5B | $2.7B |
| SolventumSOLV | $8.3B | $1.6B |
| IconICLR | $8.3B | $229M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Biogen — Key figures |url=https://companiesranked.com/en/company/biogen |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Biogen — Key figures. CompaniesRanked. https://companiesranked.com/en/company/biogenBibTeX
@misc{companiesranked-en-company-biogen-2026,
author = {{CompaniesRanked}},
title = {{Biogen — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/biogen}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000875045-26-000013 · February 6, 2026
{{cite web |title=Biogen — Key figures — 10-K (0000875045-26-000013) |url=https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/biib-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-06}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.